Incretin Mimetics and Risk of Acute Kidney Injury

Project number: 
Approval date: 
Monday, January 1, 1900
Principal Investigator: 
University of British Columbia (UBC)
Funding Agency: 
Not Available
Datasets requested: 
Not available
Research objective: 

We aim to study the possible association between use of incretin mimetics (DPP-4 inhibitors, GLP-1 agonists) and hospitalizations for acute kidney injury. We will answer the following specific questions:

1. Primary outcome: In patients aged 18 years and older, is exposure to GLP-1 based therapies associated with an increased risk of acute kidney injury?

Null Hypothesis 1: There is no association between GLP-1 based therapies and acute kidney injury.

2. Secondary outcome: Is there a difference of risk of acute kidney injury associated with each type of incretin mimetic?

Null Hypothesis 2: There is no difference between GLP-1 agonists or DPP-4 inhibitors in the risk of acute kidney injury.

Page last revised: July 14, 2020